- Home
- SYNX vs CHRO Comparison
SYNX vs CHRO Comparison
Compare SYNX & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYNX
- CHRO
- Stock Information
- Founded
- SYNX 2005
- CHRO 2002
- Country
- SYNX Israel
- CHRO United States
- Employees
- SYNX N/A
- CHRO N/A
- Industry
- SYNX
- CHRO
- Sector
- SYNX
- CHRO
- Exchange
- SYNX Nasdaq
- CHRO Nasdaq
- Market Cap
- SYNX 9.7M
- CHRO 8.1M
- IPO Year
- SYNX 2024
- CHRO 2024
- Fundamental
- Price
- SYNX $1.85
- CHRO $1.35
- Analyst Decision
- SYNX
- CHRO Strong Buy
- Analyst Count
- SYNX 0
- CHRO 1
- Target Price
- SYNX N/A
- CHRO N/A
- AVG Volume (30 Days)
- SYNX 26.7K
- CHRO 2.0M
- Earning Date
- SYNX 05-21-2025
- CHRO 05-14-2025
- Dividend Yield
- SYNX N/A
- CHRO N/A
- EPS Growth
- SYNX N/A
- CHRO N/A
- EPS
- SYNX N/A
- CHRO N/A
- Revenue
- SYNX $9,893,000.00
- CHRO N/A
- Revenue This Year
- SYNX $52.34
- CHRO N/A
- Revenue Next Year
- SYNX N/A
- CHRO N/A
- P/E Ratio
- SYNX N/A
- CHRO N/A
- Revenue Growth
- SYNX 18.05
- CHRO N/A
- 52 Week Low
- SYNX $1.71
- CHRO $0.45
- 52 Week High
- SYNX $6.49
- CHRO $3.80
- Technical
- Relative Strength Index (RSI)
- SYNX 30.89
- CHRO 46.67
- Support Level
- SYNX $1.74
- CHRO $1.29
- Resistance Level
- SYNX $1.94
- CHRO $1.65
- Average True Range (ATR)
- SYNX 0.16
- CHRO 0.19
- MACD
- SYNX 0.02
- CHRO 0.02
- Stochastic Oscillator
- SYNX 21.12
- CHRO 13.79
About SYNX Silynxcom Ltd.
Silynxcom Ltd is engaged in developing, manufacturing, marketing and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat-proven. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both in training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, market and sell push-to-talk devices, communication controllers, and communication device cables and connectors.
About CHRO Chromocell Therapeutics Corporation
Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic, visceral pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.